Meridian Bioscience Receives FDA Clearance For ImmunoCard(R) C. difficile GDH Test Meridian Bioscience Receives FDA Clearance for New Molecular Test: illumigene® Group B Streptococcus (November 10, 2011) Meridian Bioscience Reports Fourth Quarter and Full-Year 2011 Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2012 Guidance (August 25, 2011) Meridian Bioscience Provides Sales and Earnings Guidance for Fiscal 2012 and Comments on Fiscal 2011 Guidance (August 23, 2011) Meridian Bioscience Establishes Direct Sales in Australia Through Bioline Australia (August 9, 2011) Bioscience Launches ImmunoCard(R)C. difficile GDH Assay in Europe (June 10, 2011) Meridian Tests Detect Deadly Toxins Produced by E. coli O104 Outbreak Strain (June 7, 2011) E. coli O104 Outbreak Highlights Need for Rapid, Accurate Testing Options (April 2011) Empire Adopts Recommendations from AGA and ACG for Helicobacter Pylori Testing Meridian Bioscience Receives FDA Clearance for two new rapid tests for the detection of influenza and respiratory syncytial virus Establish a new standard of care for rapid E. coli testing with ImmunoCard STAT!® EHEC C. difficile Outbreaks Highlight Need for Rapid Testing Clostridium difficile infection in hospitals: a brewing storm Nobel Prize Awarded to H. pylori Researchers ImmunoCard STAT!® HpSA® Provides Results in 10 Minutes
Learn more about Meridian Bioscience
Copyright © 2012 Meridian Bioscience, Inc.
